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AbstrAct
Introduction Vitamin B12 is crucial for normal cell division 
and differentiation, and necessary for the development 
and myelination of the central nervous system. Pregnant 
mothers in resource poor settings are at risk for poor 
vitamin B
12 status. Poor vitamin B12 status in infancy 
is linked to poor growth and neurodevelopment. Brain 
development starts from conception, and pregnancy is a 
period of rapid growth and development for the brain.
Methods and analysis The study is an individually 
randomised double-blind placebo controlled trial in 800 
pregnant Nepalese women randomised in a 1:1 ratio. A daily 
dose of 50 µg of vitamin B
12 or placebo is given to women 
from early pregnancy, not later than week 15, until 6 months 
after birth. Weekly visits are conducted in order to record 
compliance, growth and morbidity. The primary outcomes are 
scores on the cognitive, language and motor subscales of the 
Bayley Scales of Infant and Toddler Development, Third Edition, 
measured at 6 and 12 months of age, and growth (length and 
weight) measured at 6 and 12 months of age.
Ethics and dissemination National Health and Research 
Council, Nepal (NHRC 253/2016) and Regional Committee 
for Medical and Health Research Ethics of Western 
Norway (2016/1620/REK vest) have approved the study. 
Investigators who have contributed to the conceptualising, 
conducting, as well as being involved in the data analyses 
and manuscript writing will be eligible for authorship 
and be responsible to share outcomes with different 
stakeholders through publications and workshops. 
The results from this study may support new dietary 
guidelines for Nepalese and possibly South Asian pregnant 
women that can lead to improved pregnancy outcomes, 
neurodevelopment and cognitive functioning in children.
trial registration number Universal Trial Number: 
U1111-1183-4093. Trial registration:  clinicaltrials. gov: 
NCT03071666. Protocol date: version 1.2, 1 June 2017.
bAckground
Cobalamin (vitamin B12) deficiency is 
common in many low and middle-income 
countries.1 2 This is not surprising as the main 
source of vitamin B12 is animal source foods, 
which are expensive and for cultural and reli-
gious reasons often not eaten at all. In several 
studies of women and children, we have 
demonstrated that poor vitamin B12 status 
is common in South Asia.3–5 There is also 
compelling evidence that vitamin B12 defi-
ciency occurs frequently during pregnancy,2 6 7 
and case studies have demonstrated harmful 
effects of severe vitamin B12 deficiency on the 
developing infant brain.8 9 The consequences 
of mild or subclinical vitamin B12 deficiency 
are less clear but it has been shown to be 
associated with decreased cognitive perfor-
mance in both the elderly and children.10–13 
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Protocol
strengths and limitations of this study
 ► This is a large-scale randomised controlled trial 
which aims to investigate the effect of maternal 
vitamin B12 supplement during pregnancy through 6 
months postpartum on early child development and 
growth.
 ► We are performing a comprehensive 
neurodevelopmental assessment with   tools that 
have been previously used in the same population.
 ► A potential caveat in this study is that not all 
women will have poor vitamin B12 status, and if the 
proportion of women with adequate status is high, 
this will reduce our statistical power which may 
result in failure to detect important differences.
 ► The primary outcomes will be measured when 
the children are 6 and 12 months old, beneficial 
effects of improved vitamin B12 status of the mother 
might not be measurable in the children until later 
childhood.
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have measured the effect of vitamin B12 supplementation 
on neurodevelopment in children: In a Norwegian trial, 
an intramuscular injection of B12 substantially improved 
the motor development in 6-week-old infants after 
1 month,14 another intervention study in low birthweight 
children recently confirmed these findings.15 The infants 
in these studies had evidence of suboptimal vitamin B12 
status, but none was severely deficient. We found a bene-
ficial effect of vitamin B12 supplementation for 6 months 
on neurodevelopment in young North Indian children.16 
In this study, where the children were supplemented 
daily with two recommended daily allowances (RDA) for 
6 months, the effect of vitamin B12 supplementation was 
more apparent in children who had evidence of vitamin 
B12 deficiency at the start of the study.
During pregnancy, vitamin B12 is concentrated in the 
fetus and stored in the liver.17 18 Infants born to vitamin 
B12-replete mothers have stores of vitamin B12 that are 
adequate to sustain them for the first several months post-
partum. Consequently, vitamin B12 deficiency rarely occurs 
before the infant is about 4 months old if the mother has 
adequate vitamin B12 status during pregnancy. However, 
infants of vitamin B12-deficient breastfeeding mothers are 
vulnerable to B12 deficiency from an early age.
19
Maternal vitamin B12 deficiency has been associated 
with increased risk of common pregnancy complications, 
including spontaneous abortion, low birth weight, intra-
uterine growth restriction and neural tube defects.20–22 
Children born to vitamin B12-deficient women are at 
increased risk for adverse health outcomes, including 
developmental abnormalities and anaemia.9 23 In a recent 
RCT in Bangalore, India, daily maternal vitamin B12 
supplementation (50 µg/day) during pregnancy through 
6 weeks postpartum substantially improved maternal 
vitamin B12 status and increased breast milk and infant 
plasma vitamin B12 concentrations.
24 In this study, the 
proportion of children being born small for gestational 
age was lower in the vitamin B12 group than in the placebo 
group (25% vs 34%); however, no difference was found 
in neurodevelopment in infants at 9 months of age.25 
Similar improvements in vitamin B12 status were found 
among Bangladeshi mothers and infants when supple-
mented with 250 µg of vitamin B12 from 11 to 14 weeks of 
pregnancy through 3 months postpartum.26 In this study, 
women who were randomised to receive vitamin B12 also 
had an improved immune response to the pandemic 
influenza A (H1N1) vaccine.
The first 1000 days after conception are regarded as 
the most critical time for brain development. During 
this period, brain growth is rapid, increasing the suscep-
tibility to influences from the environment.27 This is 
also the period when most of the myelination of the 
brain occurs.9 In infants, moderate and severe vitamin 
B12 deficiency has been associated with demyelination 
and brain atrophy.28 29 Little is known about the conse-
quences of maternal vitamin B12 deficiency for early 
brain myelination, neurodevelopment and cognitive 
function.
Hypothesis to be tested
In Nepalese women, daily supplementation of 50 µg 
vitamin B12 from early pregnancy, not later than week 
15, and until 6 months postpartum, improves linear and 
ponderal growth as well as cognitive, language and/or 
motor scores of the Bayley Scales of Infant and Toddler 
Development, Third Edition (Bayley-III) in their infants.
specific objectives
Primary objectives
1. Measure whether daily maternal administration of 
50 µg vitamin B12 from early pregnancy until 6 months 
postpartum improves cognitive, language and motor 
scores of the Bayley-III measured at 6 and 12 months 
of age.
2. Measure whether daily maternal administration of 
50 µg vitamin B12 from early pregnancy until 6 months 
postpartum improves the infant’s z-scores length 
for age, weight for age and weight for length at 12 
months.
Secondary objectives
1. Measure whether daily maternal administration 
of 50 µg vitamin B12 from early pregnancy until 
6 months postpartum improves haemoglobin 
concentration of the mother and infant, and also 
assess the relationship between maternal and infant 
haemoglobin concentration on cognitive outcomes at 
6 and 12 months of age.
2. Measure whether daily maternal administration of 
vitamin B12 from early pregnancy until 6 months 
postpartum improves cognitive function of infants as 
measured by the Bayley-III at 24 months of age.
3. Measure whether daily maternal administration of 
vitamin B12 from early pregnancy until 6 months 
postpartum improves development as measured by the 
Ages and Stages Questionnaire, Third Edition (ASQ-
3), at 6 and 12 months of age.
4. Measure whether daily maternal administration of 
vitamin B12 from early pregnancy until 6 months 
postpartum improves motor function of infants as 
measured by the Test of Infant Motor Performance 
at 45 days.
5. Measure whether daily maternal administration of 
vitamin B12 from early pregnancy until 6 months 
postpartum reduces the risk of complicated deliveries.
6. Measure whether daily maternal administration of 
vitamin B12 from early pregnancy until 6 months 
postpartum reduces the risk of giving birth to a child 
small for gestational age.
7. Explore the efficacy of vitamin B12 on growth and 
development in various subgroups (defined before 
the randomisation code that links the group treatment 
to a study participant is broken).
8. Measure whether daily maternal administration of 
vitamin B12 from early pregnancy until 6 months 
postpartum alters sleep and activity patterns of the 
infant.
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Figure 1 Study flow chart—recruitment, supplementation and follow-up plan. BSID, Bayley Scales of Infant Development.
9. Measure whether daily maternal administration of 
vitamin B12 from early pregnancy until 6 months 
postpartum affects heart rate variability.
MeThods
study setting
The study site is located in Bhaktapur, 15 km east of the 
capital city Kathmandu. Bhaktapur city is an ancient 
city famous for its traditional temples and buildings. 
It is listed under Unesco world heritage and one of 
the main tourist attractions in Nepal. Bhaktapur is a 
homogenous community consisting mostly of practising 
mixed Hindus and Buddhists. It is a periurban agri-
cultural-based community located 1400 m above sea 
level with a population predominated by the Newar 
ethnic group. In the Bhaktapur municipality, domestic 
migrant workers from diverse ethnic groups work in 
several carpet factories. The local climate is humid 
subtropical with a wet and hot season (monsoon) from 
May to August, and a dry and cool season from October 
to March. The annual average rainfall is 78.3 mm, 
and the temperature ranges from −2°C to 35°C. The 
majority of the residents in Bhaktapur consume foods 
grown in the community. Rice is the staple food. The 
eating pattern varies with season, workload in the field 
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and availability of foods. A variety of local green leafy 
vegetables is widely consumed mainly in the winter and 
spring seasons.
Eligibility criteria
1. 20 to 40-year-old pregnant women from early 
pregnancy, not later than 15 weeks pregnant;
2. residing in Bhaktapur municipality and surrounding 
areas in Bhaktapur district;
3. availability of informed consent.
exclusion criteria
1. taking dietary or multivitamin supplements containing 
vitamin B12;
2. known cases of chronic disease under treatment 
such as tuberculosis, diabetes, hypertension, hypo or 
hyperthyroidism, pernicious anaemia, Crohn’s disease 
and current use of anticonvulsant drugs;
3. severe anaemia (haemoglobin concentration <7 g/
dL); blood will be analysed for haemoglobin 
concentration immediately after collection at 
enrolment by using HemoCue;
4. suffering from any condition that requires treatment 
with vitamin B12 such as pernicious anaemia and strict 
vegans.
Intervention
The supplements are produced by GC Rieber Compact 
(Bergen, Norway). The vitamin and placebo tablets are, 
except for the cyanocobalamin content, identical in 
composition, taste, smell and appearance. The composi-
tions of the tablets follow the recipe of the commercial 
product ‘Seven OceanS Emergency Ration.’ Each daily 
dose (placebo or 50 µg vitamin B12) also contains 31 
kcal from the 6.95 g vehicle which mainly consists of 
dextrose and palm oil. First dose of supplementation will 
be given by research staff at the hospital, and mothers 
will then be instructed to properly store the supple-
ments, and consume these every day preferably in the 
morning. During the weekly visits, our research staff 
will record consumption of supplement during the last 
7 days including iron, folic acid and calcium, and also 
count the amount of remaining supplements. We will also 
record if there was vomiting after supplementation, and 
reasons why the supplements were not taken. During the 
antenatal visits or other visits at the hospital, the study 
gynaecologists will verify the compliance. Additionally, 
study supervisors will randomly select days (5% of total 
days) to make independent visits to participant’s mother's 
home in order to record compliance with supplementa-
tion.
cointervention
All pregnant women will also be given folic acid (0.4 mg) 
for the first 2 months of pregnancy followed by iron (60 mg 
elemental iron) and calcium supplements (500 mg) until 
45 days after delivery according to the WHO guidelines.30
recruitment procedure, confirmation of pregnancy and 
assessment of gestational age
Prior and throughout the study period, we will identify 
pregnant mothers through a hospital and communi-
ty-based surveillance system (figure 1). We have records 
of newly married couples in the study area that are 
updated quarterly. Information regarding pregnancies 
will be obtained monthly by household surveys or phone 
calls. Women with history of interrupted menstruation 
cycle or pregnancy detected by standard human chori-
onic gonadotropin kits, are screened in the hospital. In 
these women, pregnancy and gestational age is estimated 
by ultrasonography (USG). Follow-up USG is performed 
between 18 and 22 weeks for anomalies scanning.
After screening for eligibility, a detailed information 
regarding the study will be provided focusing on the dura-
tion, collection of biological samples and the follow-up 
plan of the study. The consent forms will be filled up by 
study gynaecologists or supervisors, preferably in the pres-
ence of the husband. A copy of the consent form along 
with the information sheets will be provided to each partic-
ipant. In the consent form, there is a separate provision 
for consent of biological samples where the participants 
may agree or refuse. In case of illiterate participants, we 
will obtain thumbprints after getting signature from an 
impartial witness who is not part of research team.
Allocation, randomisation and blinding
The randomised allocation list was generated in STATA 
(Stata, College Station, TX) using the script ‘randomize’ 
(net from http:// folk. uib. no/ mihtr/ stata/). We 
randomised the women in a 1:1 ratio in blocks of 8. Each 
woman is assigned a packet of supplementation according 
to her ID number which is sequentially numbered. This 
packet is only labelled with general information about 
the study and the unique ID number. The list that links 
the ID number to the randomisation code is kept with 
the company that produces the intervention and the 
placebo, and with the scientist who generated it who is 
otherwise not involved in the study. We will ensure allo-
cation concealment throughout the study as none of the 
investigators will have access to this list until completion 
of data collection. This is only after the database with the 
main outcomes (growth and neurodevelopment scores) 
has been cleaned and locked, and after the plan of anal-
ysis for the main outcomes is finalised and approved by all 
involved scientists.
rationale for choosing 50 µg dose of vitamin b12
Based on results from previous studies in this area, we 
expect the intake of vitamin B12 among women in our 
study to be low, both due to a predominant plant-based 
diet and poor gut function that again may disturb vitamin 
B12 absorption and increase dose requirements. Absorp-
tion of vitamin B12 is strictly regulated, and the body is 
not able to absorb more than 2–4 µg/day. The vitamin B12 
supplementation study in pregnancy from South India24 
and the study from Bangladesh26 used very high doses of 
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20–100× RDA with no reported adverse effects. There are 
other large RCTs where similarly high doses of vitamin B12 
have been given together with other micronutrients.31 32 
These studies found that the micronutrient mixture that 
included high doses of vitamin B12 reduced the risk for 
small for gestational age (SGA) with no adverse effects. 
In Europe and the USA, vegans and vegetarians are aware 
that there is a risk of B12 deficiency that can result in poor 
neurodevelopment and other adverse outcomes.33 Many 
therefore take additional supplements with similar high 
doses of B12 during pregnancy.
timeline
The first participant in the study was enrolled in March 
2017 and we plan to enrol for 2 years. End of follow-up 
of infants (for collecting primary outcomes) will be 
completed approximately 18 months after the last enrol-
ment.
Laboratory procedures
From the mother, blood samples will be obtained at 
enrolment (baseline) and at the end of supplementation 
(6 months postpartum). In the infants, we will collect 
blood samples at 6 months by a trained lab technician 
with direct supervision of study paediatrician. Three 
millilitres of blood will be collected into vials containing 
EDTA as anticoagulant. The plasma will be centrifuged 
at approximately 700 g at room temperature for 10 min, 
separated and transferred into storage vials, and stored at 
−70° before analysis.
The blood samples will be analysed for the following:
1. Haemoglobin concentration by using HemoCue 
B immediately after blood collection (HemoCue, 
Vedbæk, Denmark).
2. Plasma vitamin B12 and plasma folate concentrations 
will be estimated by microbiological assays using a 
chloramphenicol-resistant strain of Lactobacillus casei 
and colistin sulfate-resistant strain of Lactobacillus 
leichmannii, respectively.
3. The plasma will be stored and used for other biomarkers 
(nutrients, markers of inflammation, epigenetic 
markers and markers related to neurodevelopment).
Follow-up
We keep track of the enrolled women in a Global Posi-
tioning System (GPS)/mobile-based surveillance system. 
Enrolled women will be visited every week in the period 
of supplementation and the fieldworker will ask questions 
about their physical condition, compliance among both 
study groups and adverse events (AE). The family/women 
are asked to inform us when they go into labour, and we 
will ensure transportation to hospital where they will give 
birth. This will also ensure that we get information about 
the pregnancy outcome. We will not try to influence the 
choice of place to deliver; however, we will encourage the 
women to deliver in a health facility rather than at home. 
In the Kathmandu Valley, less than 5% of deliveries are 
at home.
After delivery, we will follow-up the child at home every 
month until 2 years of age. We will collect information on 
breast feeding and complementary feeding (frequency, 
whether other drinks or solids/semisolids have been 
given). We will also ensure that the child receives standard 
vaccines as per the expanded programme on immuni-
zation schedule. Growth will be measured and dietary 
recalls undertaken every 3 months. Neurodevelopment 
will be measured at different time points during infancy.
outcomes
Anthropometry
Weights will be measured with a portable electronic 
scale that measures to the nearest 0.01 kg (portable Seca 
weight). Height and length (portable Seca board) will be 
measured according to standard guidelines. Both length 
and weight will be measured in their homes immediately 
after birth and at 1, 3, 6, 9, 12, 18 and 24 months.
Neurodevelopment
With the exception of the Test for Infant Motor Performance 
(TIMP), all the planned assessment tools are currently 
in use in our ongoing studies in Nepal. Thus, the study 
benefits from the fact that the necessary translations, 
adaptations, piloting and psychometric evaluations have 
been completed for the study setting.
Bayley Scale of Infant and Toddler Development, Third 
Edition (Bayley-III) is a comprehensive assessment tool of 
developmental functioning in infants and toddlers aged 
1–42 months.34 It is administered directly with the child 
and provides information on functioning in cognition, 
language (receptive and expressive), motor (fine and 
gross) abilities and social-emotional functioning. The 
Bayley-III is considered to be the gold standard in devel-
opmental assessment of this age group, and is widely used 
for research purposes worldwide. Summary scores of the 
Bayley-III cognitive, language and motor subscales at 6 
and 12 months of age will be the primary outcome in 
the current study, while the assessment at 24 months will 
serve as secondary outcome.
The ASQ-3 is an easily administered checklist of devel-
opmental status standardised for children aged 1–66 
months.35 The screening system includes age-appro-
priate questionnaires for every 2/3-month intervals. 
Each questionnaire contains 30 items in five domains: 
communication, gross motor, fine motor, problem 
solving and personal social. The questionnaires are 
designed to be completed by caregivers, but can also be 
administered by a trained examiner which will be done 
in the current study. Since the ASQ-3 is a screening tool 
developed to identify children at risk for delay, there is 
a possibility for a ceiling effect. To avoid possible ceiling 
effects, children who get maximum scores will be admin-
istered the next level checklist. We have used this tool 
in the current and at a similar study setting36 previously, 
and find the tool to be a feasible addition to the assess-
ment of neurodevelopment in young children. The 
ASQ-3 will be administered in the homes of the families 
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and provide us the opportunity to assess developmental 
trajectories.
Actigraph (the Actiwatch 2 (Philips)) is a wristwatch-like 
device that records motion data. Using a validated scoring 
algorithm, the Actiware software translates the activity 
data to sleep-wake patterns and activity level. Sleep prob-
lems and sleep patterns will be further corroborated by 
questionnaire data (the Brief Infant Sleep Questionnaire 
(BISQ)). The BISQ has demonstrated good psychometric 
properties as a brief sleep screening tool for clinical 
and research purposes in infants and toddlers (0–30 
months).37
Heart rate variability (Vagal tone) is a marker of parasym-
pathetic activity. Vagal tone has been suggested to be a 
sensitive marker of self-regulation and cognitive control 
and associated with the status of vitamin B12 during preg-
nancy,38 and may be an important subjective measure 
of early risk identifier of child development. We plan to 
measure the vagal tone at 3, 12 and 24 months of age.
TIMP is a test of functional motor behaviour which 
can be used up to 4 months of age.39 40 It consists of 42 
items that are scored as present or absent based on obser-
vation. The TIMP has shown good predictive validity for 
later neurodevelopmental outcomes.41 We will pilot the 
test in the current study setting ahead of study start to 
ensure that it is appropriate for the study setting. Three 
psychologists and medical doctors will be trained through 
an online course and standardised to perform this test, 
which will be conducted when the children are 45 days to 
estimate early signs of effect of the maternal vitamin B12 
supplementation.
Questionnaires/Inventories
The Home Observation for the Measurement of the Environ-
ment (HOME Inventory) is an internationally recognised 
tool for measuring both the quality and quantity of stim-
ulation and support available to the child in the home 
environment. The tool has been used successfully in over 
100 countries and validated in several low and middle-in-
come countries.42 It consists of six subscales: parental 
responsivity; acceptance of child; organisation of the 
environment; learning materials; parental involvement; 
and variety in experience. A disadvantaged environment 
is among the many factors identified as influencing child 
cognition and development, and studies have demon-
strated that the HOME Inventory is a predictor of later 
school achievement.42 Administration of the HOME 
Inventory requires both interviewing the mother as well 
as observing the household. It takes approximately 45 min 
to 1 hour to complete, and trained fieldworkers will 
conduct this assessment. Information about the child’s 
environment will be collected so that we can account for 
the effect on child development in our study.
The Caregiver Knowledge of Child Development Inventory 
(CKCDI) is a brief questionnaire to assess parental knowl-
edge of child developmental milestones and knowledge 
of developmental stimulation.43 Parental knowledge on 
child developmental milestones may be of importance to 
promote adequate development in children. In this study, 
we will use the CKCDI in the third trimester and at 12 
months postpartum to account for the effect of the care-
givers’ knowledge on child development.
Self-Report Questionnaire (SRQ-20) is a screening of 
mental health developed by the WHO especially for low 
to middle-income countries.44 The scores on the SRQ-20 
may serve different purposes in the current study. We can 
estimate the association between maternal depressive 
scores and child development, and in addition, we may 
investigate possible effects of maternal vitamin B12 supple-
mentation on depressive symptoms.
Quality control of field activities
The fieldwork will be monitored by skilled supervisors, 
medical doctors, gynaecologists and qualified psychol-
ogists. For all outcomes, the study staff have received 
training before initiation of the project, and the staff will 
be used based on their skill level. For a specified propor-
tion (5%) of the primary outcomes, a study supervisor 
or scientist monitors the worker's performance. Some 
of these assessments are also done independently. For 
example, when a fieldworker has measured the weight 
and length of a child, a supervisor or scientist will under-
take the same measurement and compare their findings 
with that of the fieldworker. For all main outcomes, we 
compare the reliability and precision of each examiner 
with the reliability of a gold standard. For example, for 
measuring length we have training sessions where the 
fieldworkers and a gold standard measure each child 
twice. In a typical training session, each worker measures 
10 children twice. The intraindividual variability (mean 
squared difference) of a trainee will be compared with 
that of the gold standard. For length measurements, we 
will accept no more than 50% higher intraindividual vari-
ability of the examiner compared with the gold standard. 
In this exercise, we can also compare the mean deviations 
of absolute differences between the gold standard and 
the worker. The mean deviation is also compared with the 
mean variability of the measurements of the gold stan-
dard. The deviation is also compared on a qualitative scale 
to assess whether there are systematic higher or lower 
readings. In case of poor agreement, extra training will 
be carried out until acceptable agreement was achieved.
Quality control for the neurodevelopmental tools
All methods that will be used to measure neurode-
velopment have been translated, adjusted and/or 
piloted in previous studies at the current study site. 
The comprehensive neurodevelopmental tools such as 
the Bayley-III and TIMP will be administered by the 
medical doctors and psychologists. Medical doctors 
and qualified psychologists will train and monitor 
fieldworkers to perform the neurodevelopmental 
assessments such as the ASQ-3, HOME assessment 
and the various questionnaires. Ahead of study 
start, we will arrange training sessions. The trainings 
will be supervised and monitored by experienced 
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Table 1 Expected losses to follow-up due to different 
conditions during the study period
Expected losses to follow-up (%)
Late abortions 5
Dropouts during pregnancy 4
Dropouts during infancy, including infant mortality 6
psychologists from the Regional Centre for Child and 
Adolescent Mental Health and Welfare, Uni Research 
Health, Bergen, Norway. Standardisation exercises will 
be conducted measuring the inter-rater reliability of 
the assessor compared with a gold standard until satis-
factory level of agreement. Video recording will be 
done for all Bayley assessments and 10% of the videos 
will be scored independently for quality control. For 
all other instruments, 5% of the assessments will be 
double scored. Once a month inter-rater reliability will 
be analysed for quality control.
safety considerations, safety monitoring and AE reporting
All AEs and serious adverse events (SAE) will be 
recorded by the study staff. AEs are graded from 1 to 
5 according to their severity according to Common 
Terminology Criteria for Adverse Events.45 All imme-
diate AEs following each dose of intervention will be 
documented for all women.
All AEs will be followed up until resolution or stabi-
lisation as judged by gynaecologist or paediatrician 
(site investigator) and the principal investigator. All 
SAEs will be followed up until satisfactory resolution 
or until the treating physicians and the principal inves-
tigator deem the event to be chronic or the participant 
to be stable.
SAE, which includes critical or life-threatening 
illness or death, will be documented from the time of 
enrolment throughout the study period. The pregnant 
women will be visited every week. During each contact, 
the study staff will collect data to ascertain SAEs and 
illness requiring hospitalisation. All SAEs of death, 
development of signs of critical illness and severe 
illness requiring hospitalisation, and AEs as described 
previously will be reported to the Ethics Committees, 
the Data and Safety Monitoring Board (DSMB) and to 
the sponsors of the study within 24 hours of awareness 
of the event, followed by a final report within 10 days. 
SAE’s relatedness to the administration of vitamin 
B12 or placebo will be judged by the investigator/
designee, the Ethics Committee and the DSMB who 
will have access to all relevant investigations, clinical 
assessments and if require unblinding allocated inter-
ventions.
data and safety Monitoring boards
The DSMB comprises a paediatrician, public health 
expert and a biostatistician. The DSMB is indepen-
dent from the sponsor and has no competing interests. 
The DSMB members have prepared a charter and 
decided the study stopping rules, and will review 
the SAEs and AEs reported in the study periodically. 
They will examine all pregnancy complications, 
cases of severe illness, infant deaths and other SAEs 
to decide if the study should be continued, based on 
the predecided stopping rules. After one-third of the 
study participants have been enrolled and completed 
follow-up, the DSMBs will review the data and make 
recommendations concerning continuation, modifica-
tion or termination of the study due to unexpectedly 
large beneficial effects or serious side effects and 
can suggest extension of the trial should the primary 
outcomes occur less often than anticipated. Any 
important protocol modification such as changes to 
eligibility criteria, outcome analyses will be thoroughly 
communicated with DSMB members and will obtain 
amendment clearance from the institutional review 
board (IRB).
sample size calculations
We expect that as many as 15% of the enrolled women 
will be lost to follow-up because of abortions, stillbirths 
and migration (see table 1).
We have calculated the sample sizes based on standard 
formulas46 to compare two means which are used in the 
‘power’ function in STATA (Stata). For an effect size 
of .25 SD, we would need to analyse 676 infants to achieve 
a statistical power of 90% (p values of 0.05); we will there-
fore target 800 women–infant dyads (676/(1–0.15)). In 
these calculations, we assumed equal SD in the placebo 
and vitamin B12 groups. The power to detect differences 
between the study groups is larger than what is projected 
here as we will measure most of the outcomes more than 
once and also use these repeated measurements in the 
same analyses, adjusting for interdependence within a 
child using mixed effects models, generalised estimating 
equations or other appropriate methods. Various required 
total sample sizes according to meaningful differences 
and powers of 80% and 90% are depicted in figure 2.
These figures are based on national figures and our 
experiences from the field site. Infant morbidity and 
mortality are expected to be lower than national figures 
because of the proximity to the capital Kathmandu and 
because of our close follow-up.
data management
All information will be collected in structured forms 
designed specifically for this project. A relational database 
has been designed. All forms are checked manually by the 
study supervisors before they are sent for computer entry. 
All data are entered twice by two different data operators 
within 1 week of data collection.
Data are stored in secure servers in the field office and 
in a data management centre (DMC) in Kathmandu. A 
substantial proportion of the forms is captured using iPads 
or similar tablets using the cloud-based data management 
system. We have used this electronic data capture system 
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Figure 2 Estimated required total sample sizes based on relevant effect sizes at 80% and 90% power.
with success in many previous studies. Only computer 
data entry staff and supervisors will have access to the 
data. In the data system, the entered data are processed 
in several steps and the system will be designed to identify 
inconsistencies between different variables and different 
forms. The system can also detect entries that are out of 
range and notify when information is missing. This system 
also includes reminders about study activities, that is, the 
study staff will be notified when a birth or a scheduled 
vaccine is due. We are collecting GPS coordinates and 
phone numbers from several family members. By this, 
we can more easily reach the families and will probably 
reduce the numbers of missed home visits.
data tracking, cleaning and quality checks
The DMC is also responsible for initial cleaning of the 
data. Interim tabulations and scatter plots for some vari-
ables will be made at regular intervals to identify data 
errors. Special checks are made on observations that are 
more than two or three SDs from the mean. There is a 
regular feedback of errors from the DMC to the study 
sites.
record retention and archival
All the study documents including participant’s source 
data and documents will be archived by the study sites 
after the completion of the study, until the time the 
sponsor informs in writing to the study sites that they no 
longer need to maintain the study documents.
Plan of analysis
All analyses will initially be done on an intent-to-treat basis. 
All randomised participants will be included in the anal-
yses if the relevant outcome variables have been collected. 
The main outcomes are continuous and expected to be 
normally distributed. We will use the Bayley-III scores at 6 
and 12 months in separate analyses where B12 supplemen-
tation is the main exposure. We will compare the mean 
Bayley-III scores (scores on the cognitive, language and 
motor subscale scores, with the language scale analysed 
both separately for receptive and expressive language and 
as a composite measure, and the motor scale analysed 
both separately for fine and gross motor development 
and as a composite measure) between the vitamin B12 
group and the placebo group. For growth, the main 
outcome will be measured when the child is 12 months. 
Linear growth, expressed as centimetres and height for 
age z-score (HAZ), and weight expressed as kilograms, 
weight for age (WAZ) and weight for height (WHZ) 
will be compared between the study groups. If baseline 
differences are observed, we will adjust these imbalances 
in multiple linear regression models, adjusted and unad-
justed effect estimates will then be presented.
We will analyse the effect of vitamin B12 separately in the 
following subgroups:
1. Vitamin B12 status:
 – based on cobalamin (cut-off: 150 pmol/L)
 – based on low total homocysteine (cut-off: 10 
µmol/L)
 – based on low methylmalonic acid (cut-off: 0.26 
µmol/L)
2. Maternal body mass index (cut-off: 18.5)
3. Vegetarian (yes/no)
4. Birth weight (cut-off: 2500 g)
In these subgroup analyses, the differences in the effect 
between the levels of the subgroups will be measured by 
group.bmj.com on March 6, 2018 - Published by http://bmjopen.bmj.com/Downloaded from 
 9Chandyo RK, et al. BMJ Open 2017;7:e016434. doi:10.1136/bmjopen-2017-016434
Open Access
including two-way interaction terms in multiple regres-
sion models. Statistically significant effect modification 
will be when the p value of the interaction term is <0.05.
Per protocol analysis
In addition to a standard per protocol analysis, we will 
use instrumental variable analysis in an attempt to esti-
mate the true effect of cobalamin had it been given to all 
women in the scheduled doses and intervals. The random 
allocation will be the instrument in these analyses. For 
per protocol analysis, women who receive less than 50% 
of the projected doses during pregnancy will not be 
included in the analyses, well acknowledging that the 
ensuing effect estimates may be biased and will certainly 
represent an effect higher than what can be achieved 
even in our well-resourced study setting.
dIscussIon
This proposed study measures the effect of vitamin B12 
supplementation from early pregnancy through 6 months 
postpartum on early neurodevelopment and growth in 
800 Nepalese infants at 6 and 12 months. Randomised 
clinical trials on vitamin B12 in pregnancy are called 
for as concluded in a recent systematic review and 
meta-analysis.22 This trial will add to the knowledge on the 
potential beneficial effects of vitamin B12 on pregnancy 
and perinatal outcomes.21 Our results can be used to 
inform both regional dietary guidelines for Nepalese and 
South Asian pregnant women. The recently published 
report ‘WHO recommendations on antenatal care for a 
positive pregnancy experience’ only recommends iron 
and folic acid to pregnant women,30 the results from our 
study may possibly contribute to necessary updates of 
these guidelines.
The primary concern raised by the Norwegian IRB 
was that this RCT was violating the principle of clin-
ical equipoise. The IRB was accordingly concerned 
that we were withholding necessary vitamin B12 treat-
ment for those who were randomised to the placebo. 
This concern was based on comments from an expert 
reviewer appointed by this IRB, and we are dealing 
with this concern, in part, by measuring functional 
motor behaviour by the TIMP when the children are 
45 days in the first 100 children. If we find an unex-
pected beneficial effect of vitamin B12 on the results 
of this test, the DSMB will consider stopping the trial. 
The TIMP was added solely based on the concerns 
raised by the IRB, and this motor test will mainly be 
used as a tool for the DSMB when deciding whether 
the study should continue or not. It should also be 
noted that before approving our protocols, the IRB 
engaged a second external expert who did not share 
the concerns regarding clinical equipoise.
The Government of Nepal, in partnership with 
different organisations such as WHO and Unicef, has 
initiated many programmes in mother and child care. 
There are great concerns that many children in low 
and middle-income countries fail to reach their devel-
opmental potential due to poverty-related factors such 
as malnutrition, micronutrient deficiencies, parental 
illiteracy, and lack of stimulation and learning oppor-
tunities.47 Results from our study will provide a valuable 
contribution to the field of early risk and development 
in disadvantaged children and their families, and may 
also help to further integrate the Government of Nepal 
programme on the first 1000 golden days.
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